View in EDS

1015eTiP Beamion BCGC-1: A phase Ib/II, randomized, open-label, multicenter trial of oral zongertinib, alone or in combination, for the treatment of advanced HER2-positive metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC)

Saved in:
Bibliographic Details
Title: 1015eTiP Beamion BCGC-1: A phase Ib/II, randomized, open-label, multicenter trial of oral zongertinib, alone or in combination, for the treatment of advanced HER2-positive metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC)
Authors: Hurvitz, S.A.1 (AUTHOR), Simonelli, M.2 (AUTHOR), Berz, D.3 (AUTHOR), Kitano, S.4 (AUTHOR), Deng, T.5 (AUTHOR), Maier, D.6 (AUTHOR), Erzen, D.7 (AUTHOR), Aykut, S.8 (AUTHOR), Del Conte, G.9 (AUTHOR), Wang, X.10 (AUTHOR), Yarza, R.11 (AUTHOR), Nakayama, I.12 (AUTHOR), Shitara, K.12 (AUTHOR)
Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS660-S661. 2p.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1016/j.annonc.2025.08.1584